We have studied the functional expression of antigenic poliovirus fragments carried by various hybrid hepatitis B surface antigen (HBsAg) particles. Several constructions were made by using two different insertion sites in the HBsAg molecule (amino acid positions 50 and 113) and two different sequences, one derived from poliovirus type 1 (PV-1) and the other from PV-2. The inserted fragments each encompassed residues 93 to 103 of the capsid protein VP1, a segment which includes the linear part of the neutralization antigenic site 1 of the poliovirus. The antigenicity and immunogenicity of the hybrid particles were evaluated and compared in terms of poliovirus neutralization. A high level of antigenic and immunogenic activity of the PV-1 fragment was obtained by insertion at position 113 but not at position 50 of HBsAg. However, a cooperative effect was observed when two PV-1 fragments were inserted at both positions of the same HBsAg molecule. Antibodies elicited by the PV-2 fragment inserted at amino acid position 113 did not bind or neutralize the corresponding poliovirus strain. They did, however, bind a chimeric poliovirus in which the homologous antigenic fragment of PV-1 had been replaced by that of PV-2. The only virions that were neutralized by these antibodies were certain mutants carrying amino acid substitutions within the PV-2 fragment. These results show that position, constraints from the carrier protein, and nature of the inserted sequences are critically important in favoring or limiting the expression of antigenic fragments as viral neutralization immunogens.
Peptide fragments used as antigens and immunogens are valuable tools for analyzing the antigenic structures of proteins and microorganisms and have raised new possibilities for creating vaccines (50) . These antigenic fragments can be obtained as chemically synthesized peptides (free or carrier bound) (43, 52) or can be produced in bacteria as recombinant, globular, hybrid proteins (54) . When injected into animals, such immunogens usually induce anti-peptide or anti-protein antibodies but rarely elicit antibodies highly active against the target microorganism, partly because the configurations that peptide fragments may adopt differ from that in the original microorganism (5, 30) .
Recently, recombinant DNA methods have made it possible to present antigenic peptide fragments at the surface of virus or virus-like particles. This approach can be used to stabilize concentrated antigens on highly immunogenic particulate structures (for a review, see reference 26) . It has been successfully used to express antigenic fragments at the surface of noninfectious virus-like yeast particles (2) , hepatitis B surface (HBsAg) and core (HBcAg) antigen subviral particles (9, 14, 32, 41, 45, 48, 51) , and empty tobacco mosaic virus capsids (23) . Moreover, antigenic, chimeric, infectious particles of bacteriophage fl (44) and of poliovirus (10, 19, 29, 35, 36) can express foreign epitopes. Antigenic sequences exposed on hybrid particles have been found that induce neutralizing antibodies in animals against poliovirus (14, 23) , human immunodeficiency virus (19, 32) , and Plasmodium falciparum (41) . Immunization with hybrid HBcAg particles carrying foot-and-mouth disease virus antigens protects guinea pigs against virus challenge (9) . These systems are of value for a wide range of immunological purposes; in particular, they allow the antigenic and immuno-* Corresponding author. genic activities of viral peptide fragments to be studied in the context of heterologous, viral, antigenic structures.
Mammalian cells transformed by plasmid expression vectors carrying the S gene of the hepatitis B virus (HBV) synthesize and secrete multimeric lipoprotein particles. These HBsAg particles resemble the empty HBV envelopes found in sera of infected patients (46) . We have previously shown that in-phase insertions in one or both of the S-gene regions encoding the two hydrophilic domains of the major HBsAg protein did not prevent particle synthesis and secretion (13) . One of the inserted sequences encoded an antigenic poliovirus fragment. The poliovirus occurs as three independent serotypes (PV-1, PV-2, and PV-3), which display roughly the same antigenic structure (33, 35, 37, 53) . N-AgI, one of the four neutralization-antigenic sites of the poliovirus, mainly consists of a peptide fragment of the VP1 capsid protein; this sequence is located on a prominent loop of the viral shell (24) . We have shown that when inserted in one of the hydrophilic regions of the HBsAg molecule, a PV-1 fragment, which included the linear part of N-AgI, induced poliovirus-neutralizing antibodies in animals (14) (15) (16) .
In this work we have analyzed how structural factors influence the antigenic and immunogenic activity of the N-AgI fragment when the fragment is borne by various HBsAg poliovirus particles. Several constructions were made with two different insertion sites in the HBsAg molecule (one in each of the two major hydrophilic regions) and two homologous fragments, one derived from PV-1 and the other from PV-2. The antigenicities and immunogenicities of these hybrid particles were evaluated and compared in terms of poliovirus neutralization. The results not only revealed critical aspects of the structural relationships among carrier protein, inserted sequences, and target virus, but also pro-HYBRID HBsAg-POLIOVIRUS PARTICLES 6091 vided a basis for manipulating the activities of antigenic fragments presented on hybrid particulate antigens.
MATERIALS AND METHODS
Recombinant plasmids. To construct the plasmids pPAP and pPAL, synthetic BamHI fragments were ligated to BamHI-cleaved pLAS (Fig. 1A) . For plasmids pBAP and pDAP a synthetic DNA fragment was ligated to BalI-treated pLAS and pPAP, respectively. Transformants were screened for recombinant plasmids by in situ hybridization using 32P-labeled oligonucleotides and by polyacrylamide gel electrophoresis (PAGE) after BstNI digestion. The inserted region of recombinant plasmids was sequenced according to the method of Sanger et al. (42) .
Cell culture, detection, and purification of hybrid proteins. Mouse L cells were grown in Dulbecco's modified minimum essential medium supplemented with 10% newborn calf serum and 50 ,ug of gentamicin per ml. Each recombinant plasmid was cotransfected with the plasmid pW, encoding G418 resistance (11) , by using the phosphate calcium technique as previously described (16) . Colonies appearing after transfection were grown to confluence, and supernatants were tested for HBsAg with the Enzygnost HBsAg microimmunoassay (Behring). For the purification of antigens, the supernatants of HBsAg-producing cellular clones were clarified, and a saturated solution of ammonium sulfate, pH 7.5, was added to a final concentration of 50%. The precipitate was collected by centrifugation, dissolved in TNE buffer (10 mM (16) . Alternatively, the first incubation was performed in the presence of 1% Triton X-100-0.1% SDS-1% sodium deoxycholate.
Enzyme-linked immunosorbent assay. Microtitration plates were coated with 100 ,ul of a 1-pug/ml antigen or peptide solution in PBS for 16 h at 4°C and washed with 0.5% Tween 20 in PBS. The plates were then saturated with the same solution containing 3% bovine serum albumin (BSA) and incubated with various dilutions of MAbs or rabbit sera in PBS-Tween 20-1% BSA for 2 h at 37°C. Peroxidase-labeled goat anti-mouse or anti-rabbit immunoglobulin G was used to detect bound antibodies. Alternatively, a first-step reaction was performed by using peroxidase-labeled rabbit anti-human HBsAg (Behring). The two antibody sandwich immunoassays were performed by using the MAb C3-containing ascites fluid (1:500 dilution) for coating. Fixed antigens were revealed by using the peroxidase anti-HBsAg antibodies.
Immunization P-mercaptoethanol for 10 min at 95°C and then diluted 20-fold in RIPA buffer. Immunoprecipitation was performed with rabbit sera at a 1:50 dilution and protein A-Sepharose, as described above for the HBsAg product.
Poliovirus neutralization. The titer of neutralizing antibodies in each serum sample was measured by a standard plaque reduction assay on Vero cells, with an input of 100 PFU of poliovirus. The reciprocals of the dilutions of serum samples giving 50% plaque reduction were computed from the regression curves of mean values obtained in at least two independent experiments. Alternatively, an infectivity inhibition assay was performed by using 10 poliovirus 50% tissue culture infectious doses.
Anti-HBsAg antibodies. Anti-HBsAg titers were determined with the AUSAB radioimmunoassay (Abbott Laboratories) according to the semiquantitative method recommended by the manufacturer.
RESULTS
Construction of recombinant plasmids. In the pLAS plasmid, the S gene, encoding the 226-amino-acid major envelope protein of HBsAg, is expressed from the simian virus 40 the plasmids pPAP (14) and pPAL. This led to duplication of amino acids 112 and 113 of HBsAg and insertion of an 11-amino-acid sequence between the duplicated residues (Fig. 1A) . The sequences inserted into pPAP and pPAL encode amino acid residues 93 to 103 of capsid protein VP1 of PV-1 Mahoney strain and PV-2 Lansing strain, respectively (Fig. 1B) . These sequences, which differ from each other at 6 of the 11 residues, are part of poliovirus N-AgI. The PV-1 fragment carries a neutralization epitope (C3) recognized by MAb C3 (4, 49). The PV-2 sequence reacts with two MAbs, Ilo (12) and H02 (a generous gift from A. Osterhaus, described as 10C9E6 in reference 47), when exposed at the surface of the Lansing strain or when carried by a type 1/type 2 chimeric poliovirus in which the N-AgI fragment of PV-1 was substituted by that of the PV-2 virus (29) .
The plasmids pBAP and pDAP were constructed by inserting a 36-bp synthetic DNA fragment at the BalI site of the S gene carried by the plasmids pLAS and pPAP, respectively (Fig. 1A) . The insertion encodes the 11-amino-acid fragment which carries the C3 epitope of PV-1 between the duplicated amino acid residue 50 (Gly) of HBsAg. Therefore, the plasmid pDAP encodes a hybrid protein which bears two copies of the PV-1 fragment, one at amino acid position 50 and the other at amino acid position 113 of HBsAg (Fig. 1B) .
Synthesis and characterization of hybrid HBsAg particles.
Each plasmid was mixed with plasmid pW (11) encoding G418 resistance and cotransfected into mouse L cells as described above. G418-resistant transfectants were screened for HBsAg expression by enzyme immunoassay, and positive clones were isolated. Those clones producing the highest levels of antigen were selected for antigen characterization and purification. The HBsAg-related products were purified on successive CsCl density gradients. All hybrid particles banded between 1.20 and 1.22 g/cm3, a density similar to that of HBsAg particles from pLAS and from sera of HBV-infected humans. Direct visualization by using electron microscopy showed that the hybrid HBsAg molecules were assembled into particles roughly similar to HBsAg from human serum (Fig. 1C ). When polypeptides of purified antigens were subjected to PAGE, two major bands appeared in the 23-to 30-kDa range, corresponding to the nonglycosylated and glycosylated forms of the protein, respectively (Fig. 1D ). The differences among the apparent molecular sizes of the various HBsAg proteins lacking or carrying insertions are in good agreement with the lengths of the amino acid sequences encoded by the inserts. Moreover, extensive silver staining of polyacrylamide gels showed, for each construct, two minor, higher bands with apparent molecular masses of around 40 and 50 kDa. These may be unreduced dimers of glycosylated and nonglycosylated poly-J. VIROL. peptides, as described by Mishiro et al. (34) (Fig. 2, lanes 1,  4, 7 , and 10).
Trypsin sensitivity of HBsAg particles carrying the PV-1 fragment. In an attempt to establish whether the inserted poliovirus sequence was exposed at the surface of the particles and to examine whether it had created conformational changes in the envelope protein, we studied the protease sensitivities of HBsAg particles carrying the PV-1 fragment (HBsPVlAg) (Fig. 2) . Unmodified HBsAg particles are highly resistant to trypsin under nonreducing conditions (Fig. 2, lane 2) . In the presence of a reducing agent, HBsAg is cleaved exclusively at Arg-122 (39) (Fig. 2, lane 3) .
When HBsPVlAg PAP particles (insertion at amino acid position 113 of HBsAg) and DAP particles (insertions at amino acid positions 50 and 113) were treated with trypsin under nonreducing conditions, almost all molecules were cleaved at a unique site (or several closely spaced sites) (Fig.  2, lanes 5 and 11) . The sizes of the fragments are compatible with a cleavage within the sequence inserted at amino acid position 113 of HBsAg, as previously described for PAP particles (14) . Under the same conditions, the HBsPVlAg BAP particles (insertion at amino acid position 50 of HBsAg) were more resistant to trypsin; nevertheless, BAP particles were partially cleaved into fragments of 19.5 and 6.4 kDa (Fig. 2, lane 8) . This suggests that the trypsin site(s) is at the Lys residue(s) in PV-1 rather than within the adjacent Arg residues at amino acid position 24 or 73 of the HBsAg molecule. Therefore, the sensitive Lys residue(s) of the poliovirus might be exposed at the surface of these hybrid particles. However, cleavage at Lys-160 or Arg-169 of HBsAg, which could yield fragments of the same size, cannot be excluded, although it is less likely. Moreover, that a proportion of molecules was sensitive to trypsin may have resulted from unintended particle disruption.
HBsPVlAg was treated with trypsin in the presence of a reducing agent. Two cleavage products were produced. The polypeptides carried by HBsPVlAg particles were com- Antigenicity of HBsAg particles carrying the PV-1 fragment. The reactivity of the hybrid particles with anti-HBsAg antibodies and the anti-poliovirus MAb C3 was tested by SDS-PAGE analysis of proteins labeled in vivo and immunoprecipitated from the cell culture supernatants of the producing clones (Fig. 3) . All particles reacted with a rabbit anti-HBsAg serum. However, only the HBsPVlAg particles were immunoprecipitated by the poliovirus-specific MAb C3. The material immunoprecipitated by the anti-HBsAg and the MAb C3 was compared for each type of particle. When the antigen-antibody incubation was performed in physiological conditions (cell culture medium), the poliovirus epitope inserted at amino acid position 50 seemed to be poorly recognized by the MAb C3 (Fig. 3A, lanes 5 and 6) . Denaturing conditions (RIPA detergents) strongly increased the binding (Fig. 3B, lanes 5 and 6) . DAP particles carrying the double insertion bound significantly greater amounts of D3d the MAb C3 in both physiological and denaturing conditions ( Fig. 3A and B, lanes 7 and 8) than particles carrying a single insertion. For a more quantitative view of the reactivity of each kind of particle with the HBsAg antibodies and the MAb C3, antibody capture assays were performed by using purified particles as coating antigens and various dilutions of antibodies (Fig. 4) . The insertion at amino acid position 113 of HBsAg caused a reduction in the binding of the HBsAg rabbit antibodies, as compared with unmodified HBsAg (14) . Insertion at amino acid position 50 had no effect. In agreement with the results of the immunoprecipitation experiments, MAb C3 reacted more poorly with the BAP particles than with the PAP and DAP particles. DAP particles carrying the double insertion reacted best with the MAb C3. These results were confirmed by antibody sandwich immunoassays using MAb C3 as a coating reactant and peroxidase-labeled HBsAg antibodies to detect and quantify the bound particles. The concentrations of HBsPVlAg giving the same absorbance as a concentration of 5.2 jig of HBsAg LAS particles per ml were 0.15, 2.00, and 0.06 ,ug/ml for PAP, BAP, and DAP particles, respectively. The reactivity of DAP particles with the MAb C3 is higher than could be expected from the reactivities of PAP and BAP particles added together, indicating a synergism between the two insertions leading to better recognition of the MAb C3.
Immunogenicity of particles carrying the PV-1 fragment. To evaluate and compare the immunogenicities of each particle, four rabbits and six BALB/c mice were immunized with highly purified preparations of each type of antigen.
High levels of HBsAg antibodies were detected in all immunized rabbits (Fig. 5) ; the titers were stable as a function of time, and no major differences were detected among the serum samples of individual rabbits (not shown). Despite the lower reactivities of PAP and DAP particles with HBsAg antibodies when compared with LAS and BAP particles, there was no significant difference in their abilities to elicit antibodies in these animals. This appears to contra- dict our previous results indicating a low anti-HBsAg response of rabbits immunized with PAP particles (16) . The high degree of particle purity, due to the new isolation procedure used in this study, might explain both this discrepancy and the unexpected fact that five of eight rabbits showed a steep anti-poliovirus response just after the first injection (Fig. 6) . However, consistent with the antigenicity of hybrid particles, the anti-HBsAg response was lower in mice immunized with PAP or DAP particles than in mice immunized with LAS or BAP particles (Fig. 5) . That the immune response of mice and rabbits was not the same may be due to the differences in species or in the injection routes.
Despite the high level of response to HBsAg in both species (Fig. 5) , the BAP particles carrying the C3 epitope at position 50 of HBsAg did not induce detectable levels of poliovirus antibodies (Fig. 7 , data not shown for rabbits). The corresponding immune sera did not immunoprecipitate the infectious Mahoney strain of PV-1 and did not neutralize the virion. Moreover, these sera were unable to immunoprecipitate denatured poliovirus capsid protein VP1, and they reacted poorly with a synthetic peptide carrying a trimer of the amino acid 93 to 103 fragment of VP1 in antigen capture assays (Fig. 7) .
In contrast, PAP and DAP particles induced poliovirus antibodies in both rabbits and mice. All sera from the rabbits immunized with these particles contained immunoprecipitating and neutralizing poliovirus antibodies (Fig. 6) . The highest level of response was obtained 2 weeks after the first or the second injection. The level of neutralizing antibodies subsequently decreased with time. Following the third intravenous injection, a slight but consistent anamnestic response was observed in six of the eight animals. The neutralizingantibody titers were heterogeneous and in some cases were very high; two of four rabbits in each group showed a neutralizing titer of more than 3 log1o units (Fig. 6 ). Despite the fact that the serum of one rabbit immunized with DAP particles showed the highest neutralizing titer, the heterogeneousness of the response did not allow meaningful comparison of the poliovirus-specific immunogenicity of PAP and DAP particles. Pooled sera from groups of BALB/c mice immunized with PAP and DAP particles also showed immunoprecipitating and neutralizing poliovirus antibodies (Fig.  7) but at a lower level than rabbit sera. Poor responses to poliovirus-specific antigens have already been described for mice which received PAP particles (14) . However, the poliovirus-neutralizing titer in mice immunized with DAP particles was twice as high as in those immunized with PAP particles.
Although BAP particles did not induce poliovirus antibodies, these particles could prime animals for a subsequent challenge with an active poliovirus epitope. All groups of mice were given a third injection of poliovirus-immunogenic PAP particles (Fig. 7) . A high PV-1-neutralizing anamnestic response was detected in mice previously immunized with PAP and DAP particles but not in those which had received LAS and BAP particles. However, a large increase in antibodies to the poliovirus peptide (trimer of PV-1 fragment) was detected in mice previously immunized with BAP particles but not in those immunized with HBsAg LAS particles. Analogous but lower anti-peptide responses were obtained in rabbits previously immunized with BAP particles and intravenously challenged with PAP particles on day 178 (rabbits immunized with LAS particles as control) (not shown).
Antigenic and immunogenic properties of particles carrying the PV-2 sequence. (Fig. 8) . There was no difference between immune and nonimmune sera in binding to the infectious PV-2. However, the immune serum gave a stronger signal with SDS-denatured VP1 protein than the control. Therefore, poliovirus-specific anti-peptide antibodies had been synthesized. Moreover, the immune serum immunoprecipitated the infectious v510 chimeric poliovirus in which the antigenic site 1 of PV-1 Mahoney had been replaced by the corresponding amino acid sequence of PV-2 Lansing (29) . No difference was detected between the immune and nonimmune LF 17 sera in immunoprecipitation experiments using purified [35S]methionine-labeled infectious PV-1 (data not shown). This indicates that the PV-2 sequence, when exposed at the surface of the PV-1 virion, adopts a configuration which is somewhat different from that on the original PV-2. -------------------------------. ASN-------------------------------~~~~~~GLU---------------------------------------HIS------------------------------------------------------------------------- A,RG VAL- VAL-----------------------------ASN---------------------------- The poliovirus-neutralizing activity of the immune serum from rabbit LF 17, harvested 42 days after the first injection, was assayed against each of the indicated poliovirus strains. Numbers refer to amino acid residues in the poliovirus capsid protein VP1 of the PV-1 Mahoney strain in which the PV-1 sequence was substituted by that of the PV-2 Lansing strain. Amino acid substitutions in the PV-2 sequence are indicated for each antigenic variant derived from the chimeric v510 or v410 strains (29) . Neutralization of 10 poliovirus 50% tissue culture infective doses at a serum dilution of 1:10 was considered positive (+). (B) The neutralization titers were measured by a standard plaque reduction assay and expressed as the reciprocal of the end-point dilution of serum samples giving 50% plaque reduction. Serum samples were considered negative (-) for titers <1:10, the lowest dilution tested. ND, Not determined; Days, days following the first injection and corresponding to the harvest of sera; 0, preimmune serum.
Neither the PV-2 virion nor the v510 chimera was neutralized in vitro by the immune LF 17 rabbit serum. This serum sample was tested for its ability to neutralize chimeric PV-1/PV-2 poliovirus mutants which had been isolated as strains escaping neutralization with anti-PV-2 MAbs IIo or H02 (T. Couderc, A. Martin, C. Wychowski, M. Girard, F. Horaud, and R. Crainic, submitted for publication; T. Couderc, unpublished results). These antigenic variants carry amino acid substitutions within (or close to) the PV-2 sequence equivalent to that expressed in PAL HBsPV2Ag particles. Two of the ten poliovirus variants tested were neutralized by the immune LF 17 rabbit serum in screening infectivity inhibition assays (Fig. 9A) . The two sensitive antigenic variants and the parental v510 strain were tested against sera from all the rabbits (LF 17, LF 41, and LF 42) in plaque reduction neutralization assays (Fig. 9B) . The two variants were neutralized with low efficiencies by all three sera. The parental v510 strain was unaffected. No neutralization was observed with the preimmune sera nor with the immune sera from a rabbit (LF 28) immunized with PAP HBsPVlAg particles. These results indicate that HBsPV2Ag particles could express neutralization determinants present on the two sensitive poliovirus antigenic variants.
DISCUSSION
We have studied the activity of an antigenic peptide fragment, which is part of the neutralization antigenic site 1 of poliovirus, expressed on various hybrid HBsAg particles. Two different insertion sites on the HBsAg molecule and two homologous poliovirus sequences were used. The results showed how structural factors, such as the position on the HBsAg molecule, constraints from the carrier protein, and the nature of the inserted sequence, could favor or limit the expression of the antigenic fragment as a viral neutralization immunogen.
Critical role of the position of the heterologous antigenic fragment on the HBsAg molecule. When inserted at position 113 of the HBsAg, the PV-1 fragment was exposed at the surface of the hybrid PAP and DAP particles, as demonstrated both by reactivity with the MAb C3 and by trypsin cleavage experiments. The surface exposure of the PV-1 fragment correlates well with its capacity to induce poliovirus-specific antibodies. In contrast, when inserted at position 50 of the HBsAg, the PV-1 fragment was only slightly reactive with trypsin and MAb C3. Structural differences between PV-1-and PV-2-antigenic fragments. In contrast to the PV-1 fragment, the homologous PV-2 segment, inserted at position 113 of HBsAg, did not express PV-2-specific neutralization determinants. The continuous nature of some neutralization-antigenic determinants of N-AgI was demonstrated in different ways for PV-1 and PV-3 (4, 8, 18, 20, 25, 49) . The only efficient expression of the PV-2 fragment was demonstrated on chimeric PV-1/PV-2 poliovirus in which the homologous sequence of PV-1 (amino acids 94 to 102 of VP1) was replaced by that of PV-2 (29, 36) . These chimeras were neutralized by PV-2 MAbs and induced PV-2-neutralizing antibodies.
Assuming that, when inserted at the same position of HBsAg, the two homologous PV-1 and PV-2 fragments are influenced by the same surrounding residues, the observed difference in their specific activities indicates that intrinsic structural factors differentiate these fragments at the antigenic and immunogenic level. Some antigenic fragments (e.g., the PV-2 sequence) could be more sensitive to surrounding sequences than others. Antigenic variants selected from PV-2 Lansing as escaping N-AgI-specific neutralizing MAbs have amino acid substitutions in the amino acid 93 to 101 VP1 sequence (27) . Deletion at position 105, which is thought, by analogy with PV-1 (24) , not to be part of the loop carrying the linear site, makes the PV-2-antigenic site resistant to MAbs (27) . The PV-1 fragment seems to be more self-structured than its PV-2 counterpart. This might explain why the PV-1 sequence was always active when expressed in different vectors, including HBsAg (14, 16), diphtheria toxin protein (40) , or membrane and periplasmic Escherichia coli proteins (7, 28) .
An antigenic fragment of the foot-and-mouth disease virus (amino acids 141 to 160 of protein VP1) was also active as a synthetic peptide and as part of a hybrid recombinant E. coli protein or hybrid HBcAg particles (9) . Three-dimensional structure analysis of the virus showed this antigenic fragment to be a disordered, flexible, prominent loop. Its characteristics may be what allow it to retain activity when expressed in various systems (1) . The difference in activities between the PV-1 and PV-2 fragments on HBsAg particles can perhaps be explained by the relative prominence of such structural features.
Structural relationship between the immunogen and the target virus. The properties of the anti-HBsPV2Ag antisera indicated that the PV-2 sequence is expressed differently on HBsAg and on the PV-2 Lansing virus. However, experiments with these sera provided evidence that homologies may exist between HBsPV2Ag and the antibody-binding sites of the PV-1/PV-2 chimeric virus. The presentation of the PV-2 segment on the original PV-2 virion, therefore, differs from that on the chimera. This was also supported by the fact that PV-2 MAbs (e.g., MAbs IIo and H02) had different neutralizing efficiencies when tested against the two viruses (29, 36) . The viral neutralizing activities of antibodies were highly dependent on the virus structure, as indicated by the ability of HBsPV2Ag antibodies to neutralize only chimera mutants carrying amino acid substitutions in the PV-2 sequence. These results strengthen the idea that antibody binding is not sufficient to provide viral neutralization. Poliovirus epitopes which lose their neutralization properties without losing their antibody-binding capacities have already been described (4) .
Antibodies elicited against synthetic peptides derived from N-AgI of PV-3 could neutralize the homologous strain and sometimes neutralized antigenic variants better than the parental strains (20) . In contrast, HBsPV2Ag antibodies had a more narrow antigenic spectrum and deviated markedly from the expected target. Stabilization of the PV-2 sequence on HBsAg may have caused this discrepancy. This observation correlates with results indicating that neutralizing antisera raised against a foot-and-mouth disease virus synthetic peptide have a wider antigenic spectrum than the corresponding anti-virion antisera (5) .
In this and some of our previous work (14, 16) , we have shown that a PV-1-antigenic fragment, when expressed at the surface of HBsAg particles, could be made highly immunogenic and could stimulate memory cells. Furthermore, if the quantity of injected antigen is taken into consideration, it would appear that HBsPVlAg can induce poliovirus-neutralizing antibodies more efficiently than equivalent synthetic peptides (8, 18, 25) . Foot-and-mouth disease virus or P. falciparum sequences are more immunogenic when expressed on HBV-derived particles than when they exist as synthetic peptides or hybrid monomeric proteins (9, 41) . These findings confirmed the efficacies of recombinant hybrid particles in presenting foreign antigens. However, the results obtained with the PV-2 fragment suggest that structural constraints might limit the expression of some antigenic sequences as viral neutralization immunogens. In this case, the experiments which consisted in finding the right target virus for a given immunogen, nevertheless suggest that the right immunogen of a given target may be identified by introducing amino acid substitutions in the original peptide sequence. Mimotopes, short synthetic-peptide sequences that mimic discontinuous epitopes, are a good example for such an approach (21, 31) .
Disulfide cyclization has been shown to increase the antigenic activities of synthetic peptides by locking their secondary structures (6, 17) . The work described here illustrates the value of detailed analysis of antigenic fragments which are locked on heterologous particulate antigens.
